{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:20:10Z","timestamp":1787167210247,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031918","name":"State Key Laboratory of Natural and Biomimetic Drugs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031918","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304297"],"award-info":[{"award-number":["82304297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574236"],"award-info":[{"award-number":["82574236"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["K202408"],"award-info":[{"award-number":["K202408"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["23PJD005"],"award-info":[{"award-number":["23PJD005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.apsb.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:54:09Z","timestamp":1768377249000},"page":"4459-4477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Scaffold hopping yields novel furo[3,2-d]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability"],"prefix":"10.1016","volume":"16","author":[{"given":"Yin-Xiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Tramontano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-8636","authenticated-orcid":false,"given":"Angela","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dettori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-2544","authenticated-orcid":false,"given":"Phuong-Thao","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-1965","authenticated-orcid":false,"given":"Xu-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-Er","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.01.010_bib1","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2026.01.010_bib2","article-title":"Rational structure-based design and optimization of next-generation biphenyl-piperidine-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors","author":"Zhang","year":"2025","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2026.01.010_bib3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.01.010_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006882","article-title":"HIV-1 reverse transcription","volume":"2","author":"Hu","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.apsb.2026.01.010_bib5","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib6","article-title":"Integrative approaches in HIV-1 non-nucleoside reverse transcriptase inhibitor design","volume":"8","author":"Poongavanam","year":"2017","journal-title":"WIREs Comput Mol Sci"},{"key":"10.1016\/j.apsb.2026.01.010_bib7","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib8","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/jm1002233","article-title":"Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design","volume":"53","author":"Lansdon","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib9","doi-asserted-by":"crossref","first-page":"19889","DOI":"10.1021\/acs.jmedchem.4c02413","article-title":"Expanding the solvent\/protein region occupation of the non-nucleoside reverse transcriptase inhibitor binding pocket for improved broad-spectrum anti-HIV-1 efficacy: from rigid phenyl-diarylpyrimidines to flexible hydrophilic piperidine-diarylpyrimidines","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd2563","article-title":"Etravirine","volume":"7","author":"Haubrich","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.01.010_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/11208590-000000000-00000","article-title":"Rilpivirine","volume":"72","author":"Sanford","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2026.01.010_bib12","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1016\/j.apsb.2025.06.016","article-title":"Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"15","author":"Chen","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.01.010_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14787210.2014.863708","article-title":"Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor","volume":"12","author":"Ripamonti","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.apsb.2026.01.010_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1742-4690-9-99","article-title":"A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants","volume":"9","author":"Johnson","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.apsb.2026.01.010_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jac\/dkt463","article-title":"Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy","volume":"69","author":"Lambert-Niclot","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2026.01.010_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116668","article-title":"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: from piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs","volume":"276","author":"Huang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib17","doi-asserted-by":"crossref","first-page":"16197","DOI":"10.1021\/acs.jmedchem.5c01102","article-title":"Probing the dominant motifs within the hydrophobic channel yields oxadiazole-containing diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib18","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.1021\/acs.jmedchem.5c00202","article-title":"Deuteration strategy-inspired design of novel diarylpyrimidine derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved efficacy, selectivity, and druggability","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib19","doi-asserted-by":"crossref","first-page":"20519","DOI":"10.1021\/acs.jmedchem.5c01695","article-title":"Exploring the HIV-1 reverse transcriptase p51\/p66 interface: structure-based design and optimization of novel 2,4,6-trisubstituted pyrimidines as potent NNRTIs with improved resistance profiles","volume":"68","author":"Ji","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib21","doi-asserted-by":"crossref","first-page":"15358","DOI":"10.1021\/acs.jmedchem.4c02237","article-title":"Halogenation-driven discovery of halomethylene-biphenyl-diarylpyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved safety and PK profiles","volume":"68","author":"Chen","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jmedchem.9b01769","article-title":"Discovery and characterization of fluorine-substituted diarylpyrimidine derivatives as novel HIV-1 NNRTIs with highly improved resistance profiles and low activity for the hERG ion channel","volume":"63","author":"Kang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib23","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acsinfecdis.0c00327","article-title":"Structure\u2013activity relationship exploration of NNIBP tolerant region I leads to potent HIV-1 NNRTIs","volume":"6","author":"Kang","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2026.01.010_bib24","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1021\/jm2007084","article-title":"Rational design of phosphoinositide 3-kinase \u03b1 inhibitors that exhibit selectivity over the phosphoinositide 3-kinase \u03b2 isoform","volume":"54","author":"Heffron","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib25","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1039\/C4MD00274A","article-title":"Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors","volume":"5","author":"Srimongkolpithak","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.apsb.2026.01.010_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113357","article-title":"Discovery of novel and potent PARP\/PI3K dual inhibitors for the treatment of cancer","volume":"217","author":"Wu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.01.010_bib27","first-page":"211","article-title":"Carbonylative transformation of aryl halides and strong bonds via cheap metal catalysts and sustainable technologies","volume":"5","author":"Yang","year":"2024","journal-title":"Green Synth Catal"},{"key":"10.1016\/j.apsb.2026.01.010_bib28","first-page":"110","article-title":"Divergent synthesis of new naphtho-fused 2-aminoindolines and naphthoxindoles based on straightforward construction of phenanthrene","volume":"6","author":"Qiu","year":"2025","journal-title":"Green Synth Catal"},{"key":"10.1016\/j.apsb.2026.01.010_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2026.01.010_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0026-895X(24)12873-8","article-title":"Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance\/sensitivity to non-nucleoside reverse transcriptase inhibitors","volume":"61","author":"Auwerx","year":"2002","journal-title":"Mol Pharmacol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:52:23Z","timestamp":1785970343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211383526000286"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.01.010","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scaffold hopping yields novel furo[3,2-d]pyrimidine NNRTIs with optimized antiviral potency, enhanced selectivity, and reduced hERG liability","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}